Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23713996 | 0.85 | HIF1A (0.47) | HIF1AFDPSHDAC1HDAC6TSHR | |
| SCHEMBL23701943 | 0.81 | HIF1A (0.47) | HIF1AFDPSHDAC1HDAC6TSHR | |
| SCHEMBL23713998 | 0.81 | HIF1A (0.41) | HIF1AFDPSHDAC1HDAC6 | |
| SCHEMBL23713997 | 0.80 | HIF1A (0.40) | HIF1AFDPSHDAC1HDAC6TDP1 | |
| SCHEMBL23701909 | 0.78 | HIF1A (0.39) | HIF1AFDPS | |
| SCHEMBL23701945 | 0.76 | HIF1A (0.46) | HIF1AFDPSHDAC1HDAC6TSHR | |
| SCHEMBL1651954 | 0.69 | FDPS (0.45) | HIF1AFDPSHDAC1HDAC6TSHR | |
| SCHEMBL28186758 | 0.68 | FDPS (0.63) | HIF1AFDPSHDAC1HDAC6TSHR | |
| SCHEMBL23713995 | 0.67 | HIF1A (0.58) | HIF1AHDAC1HDAC6TSHRTDP1 | |
| Phosphoric Acid SCHEMBL16758488 | 0.64 | FDPS (0.58) | HIF1AFDPSHDAC1HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| CN-110944664-A | Aziridines containing epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates | 威廉马歇莱思大学 | 2020-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | HIF1A 2854/4885FDPS 1142/4885PGK1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.